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Gonadoblastoma  (GB)  is  a  specific  and
unusual tumor developed by patients present-
ing a disorder of sex development (DSD). The
term gonadoblastoma was first introduced in
1953
1 to designate a steroid hormone-secret-
ing  gonadal  tumor.  This  name  was  chosen
because the neoplasm appeared to recapitulate
gonadal  development  more  completely  than
any other type of tumor. In 1970, Scully
2 report-
ed 74 cases of GB and precisely defined it as
the association of embryonic germ cells and
supportive  cells  that  resemble  immature
Sertoli/granulosa cells in a context of gonadal
dysgenesis (GD). 
First,  the  natural  history  of  GB  remains
unclear. Patient phenotypes are often female
but some degree of masculinization is possi-
ble.
3 Diagnosis is frequently made during con-
sultation for primary amenorrhea with the dis-
covery  of  Swyer  syndrome.  Tumor  secretion
may also induce the development of secondary
sexual characteristics and diagnosis after sec-
ondary  amenorrhea  has  been  described.
Patients with true hermaphroditism can also
present with GB.
Second, the predictive factors of GB develop-
ment  are  largely  unknown.  Although  Page
4
hypothesized that GB development is depend-
ent on the presence of part of the Y chromo-
some, known as the GBY region, tumor occur-
rence  remains  multi-factorial.  The  overall
tumor risk is evaluated at 30% for complete
gonadal dysgenesis and is variable for other
cases of dysgenesis. Apart from the presence of
Y material, no other risk factor has been found.
Moreover, GB can be a precursor of dysgermi-
noma, but the predictive factor for the transfor-
mation  into  an  aggressive  cancer  is  again
unknown.
3,5 An early prophylactic gonadectomy
has  thus  been  advocated  for  many  patients
with GD. In order to provide better guidelines
for  making  therapeutic  decisions  about
patients  with  DSD  and  to  prevent  abusive
gonadectomy,  we  plan  to  perform  a  clinical,
immunohistochemical  and  genetic  study  on
gonadoblastoma. Hence, we here present an
international  call  to  perform  a  multicenter
analysis of this rare tumor. The first objective
is to characterize in detail the epidemiological
factors, the diagnostic circumstances, and the
hormonal  profiles  of  patients  with  GB.  This
data collection will define the specific charac-
teristics of these patients, guide subsequent
research, and enable us to test the correlation
of these characteristics with histological crite-
ria. Then, analysis of the molecular profile of
this tumor will focus on sexual determination
factors (SOX9, FOXL2), pluripotency and dif-
ferentiation factors (OCT3/4). Both expression
of candidate genes inside the tumor and their
direct  sequencing  on  tumor  DNA  (SOX9,
FOXL2, TSPY) could provide new pathophysio-
logical insights into GB.
For  this  purpose,  we  would  appreciate
receiving the following: (i) a short report of
the  patient  history  recorded  on  a  specific
patient form and (ii) ten uncolored slides of
the tumor, with if possible frozen tissue.
Overall, the pathophysiology of GB develop-
ment is unknown. A collaborative internation-
al study will bring much needed information
on  the  connections  between  tumorogenesis
and  developmental  abnormalities,  and  could
improve the follow-up of patients with DSD,
while  reducing  the  rate  of  prophylactic
gonadectomy.
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